Prostate-specific membrane antigen (PSMA) provides an attractive target for the
development of targeted chemotherapeutics for prostate cancer. We have designed and …

Prostate cancer (PC) is the second most commonly occurring cancer in men. Conventional
chemotherapy has wide variety of disadvantages such as high systemic toxicity and low …

MLN2704 is an antibody-chemotherapeutic conjugate designed to target prostate-specific
membrane antigen (PSMA). PSMA is a transmembrane receptor whose expression is …

Simple Summary Currently, there is no effective treatment that can cure metastatic prostate
cancer. Various pros-tate specific membrane antigen (PSMA)-targeted radioimaging and …

Cell-surface markers of prostate cancer 3. PSMA as a target for cancer therapy 4. Antibody-
drug conjugate chemistries 5. Preclinical findings 5.1. PSMA ADC 5.2. MLN2704 5.3 …

Prostate cancer (PCa) is a major cause of mortality and morbidity in Western society today.
Current methods for detecting PCa are limited, leaving most early malignancies …

Prostate cancer (PC) is a potentially high-risk disease and the most common cancer in
American men. It is a leading cause of cancer-related deaths in men in the US, second only …

Background Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that
is overexpressed selectively on prostate cancer cells. PSMA antibody‐drug conjugate (ADC) …

177Lu-labeled small-molecule prostate-specific membrane antigen (PSMA) targeted tracers
are therapeutic agents for metastatic castration-resistant prostate cancer. Optimizing …

Prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals have been
successfully used for diagnosis and therapy of prostate cancer. Optimization of the available …